Compare Gilead Sciences, Inc. (GILD) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? Gilead Sciences, Inc. trades at $148.05 (market cap $182.40B), while Virgin Galactic Holdings, Inc. trades at $2.88 (market cap $445.69M). The key difference: Gilead Sciences, Inc. is far larger — about 409.3× Virgin Galactic Holdings, Inc.'s market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Virgin Galactic Holdings, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| GILD | SPCE | |
|---|---|---|
Market Cap | $182.40B | $445.69M |
Volume | 4,469,821 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $155.80 | $7.52 |
52-Week Low | $116.74 | $2.17 |
Typical Hold Time | 111 Days | 69 Days |
Enterprise Value | $205.46B | $409.68M |
Dividend Yield | 2.23% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $146.85, up 1.82% today, with a bullish technical signal from moving averages and recent earnings beats in Q4 2025 and Q1 2026. The company reported strong 2025 revenue of $29.44B and net income of $8.51B, though 2026 projections show a net loss. Key developments include a partnership with PAHO to expand HIV prevention drug access in Latin America, supporting long-term growth prospects amid mixed profitability metrics.
The outlook for GILD is cautiously optimistic, driven by analyst consensus favoring a buy rating (65.52%) and a price target of $151.57. Opportunities lie in HIV and oncology pipeline advancements, but risks include negative 2026 profit margins and high debt levels. Investors should weigh strong cash flow from operations against execution risks in a competitive biopharma landscape.
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting ongoing investor skepticism despite recent earnings beats. The company continues to burn cash with negative operating cash flow of $240.14 million in 2025 and deeply negative profit margins. Technical indicators show a bearish trend with the stock trading near key support levels. Recent news highlights management's guidance for positive cash flow by 2027 but also a delay in commercial Delta flights to February 2027.
The outlook remains highly speculative with significant execution risk. While strong ticket demand provides a potential catalyst, the path to profitability is long and dependent on successful commercial spaceflight operations. Investors face substantial dilution risk and high volatility in this pre-revenue growth phase. The stock represents a high-risk, high-reward opportunity suitable only for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
